Evidence map›Paper›PMID 26882992›Full record

ArticleScientific reports2016

Long-term safety and stability of angiogenesis induced by balanced single-vector co-expression of PDGF-BB and VEGF164 in skeletal muscle.

Roberto Gianni-Barrera, Maximilian Burger, Thomas Wolff, Michael Heberer, Dirk J Schaefer, Lorenz Gürke, Edin Mujagic, Andrea Banfi

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Vasculogenic gene therapy: No role for revitalization of structural bone allografts.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2023
    Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Therapeutic vascularization in regenerative medicine.Stem cells translational medicine · 2020
    Review
  17. Balanced single-vector co-delivery of VEGF/PDGF-BB improves functional collateralization in chronic cerebral ischemia.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2020
    Article
  18. Article
  19. Review
  20. Therapeutic vascular growth in the heart.Vascular biology (Bristol, England) · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Roberto Gianni-BarreraCell and Gene Therapy, Department of Biomedicine, Basel University, Basel, Switzerland.
Maximilian BurgerCell and Gene Therapy, Department of Biomedicine, Basel University, Basel, Switzerland.
Thomas WolffCell and Gene Therapy, Department of Biomedicine, Basel University, Basel, Switzerland.
Michael HebererCell and Gene Therapy, Department of Biomedicine, Basel University, Basel, Switzerland.
Dirk J SchaeferPlastic, Reconstructive, Aesthetic and Hand Surgery, Basel University Hospital, Basel, Switzerland.
Lorenz GürkeVascular Surgery, Basel University Hospital, Basel, Switzerland.
Edin MujagicCell and Gene Therapy, Department of Biomedicine, Basel University, Basel, Switzerland.
Andrea BanfiCell and Gene Therapy, Department of Biomedicine, Basel University, Basel, Switzerland.
University Hospital of Basel · CHDepartment of Biomedicine Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic angiogenesis by growth factor delivery is an attractive treatment strategy for ischemic diseases, yet clinical efficacy has been elusive. The angiogenic master regulator VEGF-A can induce aberrant angiogenesis if expressed above a threshold level. Since VEGF remains localized in the matrix around expressing cells, homogeneous dose distribution in target tissues is required, which is challenging. We found that co-expression of the pericyte-recruiting factor PDGF-BB at a fixed ratio with VEGF from a single bicistronic vector ensured normal angiogenesis despite heterogeneous high VEGF levels. Taking advantage of a highly controlled gene delivery platform, based on monoclonal populations of transduced myoblasts, in which every cell stably produces the same amount of each factor, here we rigorously investigated a) the dose-dependent effects, and b) the long-term safety and stability of VEGF and PDGF-BB co-expression in skeletal muscle. PDGF-BB co-expression did not affect the normal angiogenesis by low and medium VEGF doses, but specifically prevented vascular tumors by high VEGF, yielding instead normal and mature capillary networks, accompanied by robust arteriole formation. Induced angiogenesis persisted unchanged up to 4 months, while no tumors appeared. Therefore, PDGF-BB co-expression is an attractive strategy to improve safety and efficacy of therapeutic angiogenesis by VEGF gene delivery.

Indexed as

Gene ExpressionAnimalsBecaplerminGenes, ReporterGenetic VectorsMiceMuscle, SkeletalMyoblastsNeovascularization, PathologicNeovascularization, PhysiologicProto-Oncogene Proteins c-sisVascular Endothelial Growth Factor ABecaplerminProto-Oncogene Proteins c-sisVascular Endothelial Growth Factor A

Identifiers

PMID26882992
PMCPMC4756385
OpenAlexW2425206549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.